Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Michael Klichinsky"'
Autor:
Maggie Schmierer, Andrew Best, Brett Menchel, Linara Gabitova, Michael Klichinsky, Patricia Reyes-Uribe, Sascha Abramson, Sotheavy Chhum, Daniel Blumenthal, Michael Lynch
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundEngineered cell therapies have demonstrated significant clinical activity against hematologic malignancies, but solid tumors remain an intractable challenge. We have previously developed a human chimeric antigen receptor macrophage (CAR-M)
Autor:
Michael Klichinsky, Steven Kelly
Publikováno v:
Cell and Gene Therapy Insights. 5:639-645
Autor:
Benjamin A. Garcia, Saar Gill, Dylan M. Marchione, Konrad Gabrusiewicz, Kimberly Veliz, Xueqing Maggie Lu, Nicholas R. Anderson, Olga Shestova, Miriam Y. Kim, Feng Shen, Stephen R. Wallace, Michael Klichinsky, Xinhe Shan, Carl H. June, Roddy S. O’Connor, Kristin Blouch, Maksim Shestov, Marco Ruella, Yumi Yashiro-Ohtani, Miroslaw Kozlowski, Martha Zeeman, Katherine D. Cummins, Maggie Schmierer, Andrew Best, Nicholas E. Petty, Saad S. Kenderian
Publikováno v:
Nat Biotechnol
Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic malignancies, but its application to solid tumors has been challenging1–4. Given the unique effector functions of macrophages and their capacity to penetrate tumors5, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::895eb28dde195b326d70d18034d5ba3d
https://hdl.handle.net/11390/1242990
https://hdl.handle.net/11390/1242990
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background We have previously developed CAR-M as a novel cell therapy approach for the treatment of solid tumors.1 CAR-M have the potential to overcome key challenges that cell therapies face in the solid tumor setting – tumor infiltration, immunos
Autor:
Vania Aikawa, Christopher A. Hunter, Miroslaw Kozlowski, Jennifer J.D. Morrissette, Michael Klichinsky, David L. Porter, Farzana Nazimuddin, David M. Barrett, John Scholler, David A. Christian, J. Joseph Melenhorst, Michael Kalos, Saar Gill, Stephan A. Grupp, Saad S. Kenderian, Carl H. June, Marco Ruella, Olga Shestova, Simon F. Lacey, Jessica Perazzelli, Ted J. Hofmann
Publikováno v:
Journal of Clinical Investigation. 126:3814-3826
Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative rel
Autor:
Sotheavy Chhum, Michael Klichinsky, Nicholas E. Petty, Xueqing Lu, Konrad Gabrusiewicz, Xinhe Shan, Maggie Schmierer, Olga Shestova, Andrew Best, Feng Shen, Yumi Ohtani, Nicholas R. Anderson, Martha Zeeman, Saar Gill
Publikováno v:
Cancer Research. 80:3242-3242
Despite recent advances in T cell immunotherapy for the treatment of human cancer, metastatic solid tumors remain an intractable challenge. Macrophages are often the most abundant immune cell in the tumor microenvironment (TME) where, as immunosuppre
Autor:
Yumi Ohtani, Saar Gill, Daniel Cushing, Konrad Gabrusiewicz, Maggie Schmierer, Andrew Best, Michael Klichinsky, Linara Gabitova, Martha Zeeman
Publikováno v:
Cancer Research. 80:2180-2180
Despite rapid advances in cancer immunotherapy, clinical responses in metastatic solid tumors have been limited. Macrophages are the most abundant immune cell in the solid tumor microenvironment (TME) and are primarily recruited as monocytes by TME-d
Autor:
Nicholas R. Anderson, Martha Zeeman, Maggie Schmierer, Andrew Best, Saar Gill, Yumi Ohtani, Nicholas E. Petty, Katherine D. Cummins, Olga Shestova, Feng Shen, Xueqing Lu, Konrad Gabrusiewicz, Michael Klichinsky, Xinhe Shan
Publikováno v:
Cancer Immunology Research. 8:B65-B65
Despite recent advances in T cell immunotherapy for the treatment of human cancer, metastatic solid tumors remain an intractable challenge. Macrophages are usually the most abundant immune cell in the tumor microenvironment (TME) where, as immunosupp
Autor:
Christopher L. Nobles, David M. Barrett, Regina M. Young, Carl H. June, David E Ambrose, Stephan A. Grupp, Bruce L. Levine, Prachi R. Patel, Jun Xu, Hans Bitter, Frederic D. Bushman, Irina Kulikovskaya, Farzana Nazimuddin, Olga Shestova, Simon F. Lacey, Joseph A. Fraietta, Shannon L. Maude, J. Joseph Melenhorst, Vijay Bhoj, Tyler J. Reich, Michael Klichinsky, Terry J. Fry, John Scholler, Saar Gill, Marco Ruella, Elena Orlando
Publikováno v:
Nature medicine. 24(10)
We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19(-) leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was unintentionally introduced into a single leukemic B cell during T cell manufac
Autor:
Shirley Chen, Shengdar Q. Tsai, Tae Hoon Shin, Michael Klichinsky, Jennifer J.D. Morrissette, Miroslaw Kozlowski, Douglas B. Kuhns, Miriam Y. Kim, Gregory K. Behbehani, Adam Bagg, Cynthia E. Dunbar, Kyung-Rok Yu, Saar Gill, Daniel M. Schreeder, Xinhe Shan, Katherine R. Calvo, Saad S. Kenderian, Maksim Shestov, Robert E. Donahue, Aisha A. AlJanahi, Cicera R. Lazzarotto, Olga Shestova, Palak Sekhri, Marco Ruella, Katherine D. Cummins
Publikováno v:
Cell. 173(6)
The absence of cancer-restricted surface markers is a major impediment to antigen-specific immunotherapy using chimeric antigen receptor (CAR) T cells. For example, targeting the canonical myeloid marker CD33 in acute myeloid leukemia (AML) results i